On August 1, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported it will host a conference call and webcast on Thursday, August 8, 2019 at 5:00 p.m. (EDT) to discuss its financial results for the second quarter of 2019 (Press release, Navidea Biopharmaceuticals, AUG 1, 2019, View Source [SID1234538016]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jed Latkin, Chief Executive Officer, Erika Gibson, Director of Finance and Administration, and Dr. Michael Rosol, Chief Medical Officer, of Navidea, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress. Management will be available to answer questions live immediately following the earnings announcement part of the call.
To participate in the call and webcast, please refer to the information below:
Event:
Q2 2019 Earnings and Business Update Conference Call
Date:
Thursday, August 8, 2019
Time:
5:00 p.m. (EDT)
U.S. & Canada Dial-in:
877-407-0312
International Dial-in:
+1 201-389-0899
Conference ID:
13693119
Webcast Link: View Source
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s